Senti Biosciences Inc. (SNTI), which shared some promising initial clinical data for its lead drug candidate, SENTI-202, last December, is gearing up to release additional data this year.
SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy that acts by targeting cells expressing receptor type tyrosine-protein kinase (FLT3) and cells expressing myeloid cell surface antigen (CD33). CD33 and/or FLT3 are expressed in roughly 95% of acute myeloid leukemia (AML) patients.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com